In Australia, the combination of Daratumumab, bortezomib and dexamethasone (DVd) was approved by the PBAC for Pharmaceutical Benefit Scheme (PBS) listing for the treatment of Myeloma at first relapse in February 2021. The purpose of this study is to evaluate the real-life tolerability, impact on quality of life and overall treatment satisfaction of this regimen in patients enrolled on the Myeloma and related diseases registry (MRDR).
Recruitment updated as of January 2023
Information on patient-reported outcomes will be collected at various time points using the following two questionnaires: TSQM-9 and MyPOS.
These questionnaires are available in the following languages:
TRIAL PRINCIPAL INVESTIGATOR
Professor Andrew Spencer
2021 – 2024
Patients enrolled on the Myeloma and Related Diseases Registry (MRDR) with relapsed refractory multiple myeloma following one prior line of therapy and are currently receiving daratumumab, bortezomib and dexamethasone from the PBS for treatment of progressive disease.